SCHEMBL2844397

SCHEMBL2844397

Nc1cc(Oc2ccc3nc(NCC4CCCCC4)sc3c2)ncn1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 14/20 0.49
PDGFRB P09619 6/20 0.42
KIT P10721 6/20 0.42
PDGFRA P16234 6/20 0.42
FLT3 P36888 6/20 0.42
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
MAPT P10636 2/20 0.41
PKM P14618 1/20 0.41
ITK Q08881 1/20 0.39
PIK3CD O00329 1/20 0.39
PI4KA P42356 1/20 0.39
PIK3CG P48736 1/20 0.39
PI4KB Q9UBF8 1/20 0.39
MEN1 O00255 1/20 0.39
GFER P55789 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2845197 0.88 NPC1 (0.43) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2841197 0.87 CSF1R (0.46) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2843153 0.87 MAPT (0.44) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL4550946 0.86 CSF1R (0.58) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2848576 0.85 CSF1R (0.46) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL14024731 0.84 CSF1R (0.48) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2842941 0.83 WNT3A (0.46) CSF1RNPC1RAB9AMAPTPKM
SCHEMBL2846605 0.81 CSF1R (0.47) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2845075 0.81 CSF1R (0.40) CSF1RPDGFRBPDGFRAFLT3NPC1
SCHEMBL2840578 0.80 NPC1 (0.45) CSF1RPDGFRBKITPDGFRAFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 CSF1R 1/4885PDGFRB 119/4885KIT 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.